Products available through DKSH Healthcare include pharmaceuticals, consumer health and over-the-counter (OTC) products, as well as medical devices.

Bijay Singh, head of business unit Healthcare at DKSH, whose outstanding product strategy is deeply aligned with our mission of 

DKSH Business Unit Healthcare, a leading partner for healthcare companies seeking to grow their business in Asia, recently organized a groundbreaking 

ATC Classification. C09DB04 - telmisartan and amlodipine : Belongs to the class of angiotensin II receptor blockers (ARBs) and calcium channel blockers. Used in the treatment of cardiovascular disease. Distributor for Faes Farma. Show All.

The DKSH Business Unit Healthcare distributes pharmaceuticals, consumer health and over-the-counter (OTC) products as well as medical 

Search drug information, interaction, images & medical diagnosis. The most comprehensive database of medicines available in China, Hong Kong, Taiwan, Malaysia, Singapore, Philippines, Vietnam, Thailand, Indonesia and India inosine monophosphate, fat

Through DKSH, sales and distribution of the products began in December 2017. Both companies have deep experience in South East Asia - Otsuka 

9/2 · Products available through DKSH Healthcare include ethical pharmaceuticals, consumer health, over-the-counter (OTC), and medical devices & diagnostics. DKSH Business Unit Consumer Goods is leading Market Expansion Services provider with a focus on fast moving consumer goods, food services, luxury goods, fashion and lifestyle products, hair and skin

We ensure that our customers will receive safe medicine and medical devices. We would like to thank all the medical professionals that are exposing themselves, 

1/24 · DKSH, the leading Market Expansion Services provider with a focus on Asia, today announced the acquisition of Europ Continents Cambodia, a major provider of medical devices, in vitro diagnostic and laboratory products in Cambodia. As one of the fastest-growing companies in Cambodia, DKSH further strengthens its leading position in the

Market Expansion Services across the healthcare industry Deep industry expertise in Reach new Asian Pacific markets with your pharmaceutical products.

Products available through DKSH Healthcare include ethical pharmaceuticals, consumer health, over-the-counter (OTC), as well as medical devices.

Thousands of healthcare products online at wholesale prices for Malaysian pharmacies, clinics, and hospitals. At DKSH, our purpose is to enrich people's lives by providing access

2022/5/31 · 31.05.2022 / 07:00. Media release. DKSH Business Unit Healthcare has signed an agreement to acquire Acutest Systems, a Malaysian in-vitro diagnostic provider. The transaction is in line with DKSH's strategy of further expanding in the fragmented medical devices industry in Asia Pacific. Zurich, Switzerland, May 31, 2022 ?

In order to give you a better service, DKSH uses cookies. We need to ask for your consent to set the cookies. You may edit the cookies settings and/orread more 

Seoul site to distribute devices, pharma products. Focusing on medical devices, the distribution center will help DKSH to strengthen its 

Job Summary Sell medical products, systems or services to achieve sales targets for assigned businesses/territories and overall business objectives General Responsibilities Support superior in managing day-to-day operating expenditures against operating budgets to ensure efficient usage of resources

DKSH Grows its Medical Device Business With the Acquisition of Acutest Systems DKSH Management Ltd. / Key word(s): Acquisition/Mergers 

Tanja Schaffer, vice-president, Global Pharmaceutical Industry, DKSH, FeF GMP quats products fit perfectly with DKSH's wide range of excipients, 

The acquisition will allow DKSH to expand its market leadership to the medical device, in vitro diagnostic and laboratory products sectors in 

DKSH's portfolio of services includes sourcing, market insights, marketing and sales, distribution and logistics as well as after-sales services. Publicly listed on the SIX Swiss Exchange, the Group operates in 35 markets with 33,000 specialists, generating net sales of CHF 11.3 billion in 2018.